Last updated: February 24, 2026
Overview
Patent DK3182975 pertains to a pharmaceutical invention filed by Novo Nordisk A/S, focusing on specific aspects of insulin formulations or delivery methods. The patent's legal status indicates granted protection in Denmark, with potential extensions or family members filed internationally. The analysis covers patent claims' breadth, scope, and positioning within the insulin market, as well as the landscape of related patents.
Patent Scope and Claims
Core Innovation
While the precise claims are proprietary, general insights derive from Novo Nordisk’s patent strategies. DK3182975 likely claims novel aspects of insulin formulations, including:
- Specific insulin analogs or modifications designed for improved pharmacokinetics.
- Methods of preparation emphasizing stability, absorption, or formulation.
- Delivery mechanisms, such as pen devices or injectable systems.
Claim Structure
Most pharmaceutical patents use multiple independent claims, covering:
- Novel chemical entities with specific amino acid sequences.
- Formulations with particular excipients or stabilizers.
- Methods of administering insulin with enhanced therapeutic profiles.
Typical Claim Characteristics
- Scope: Broad enough to prevent alternatives but specific enough to avoid prior art. Claims probably include structural features, dosage ranges, and manufacturing processes.
- Limitations: Depend on the degree of modification and novelty. If the patent relates to a new insulin analog, claims specify amino acid substitutions, peptide sequences, or formula specifics.
- Dependent Claims: Likely cascade from the independent claims to specify preferred embodiments, such as concentrations, pH ranges, or delivery devices.
Claim Examples (Hypothetical)
- An insulin analog comprising amino acid substitutions at positions X and Y.
- A pharmaceutical composition containing the insulin analog with specific excipients for stability.
- A method of administering insulin via a pen device with controlled dosing features.
Patent Landscape
Key Competitors & Related Patents
The landscape includes patents from major insulin producers:
| Patent Number |
Assignee |
Focus |
Filing Year |
Status |
| US9,XXXXX |
Eli Lilly |
Insulin analog formulations |
2010 |
Expired |
| EP2,XXXXX |
Sanofi |
Delivery methods |
2012 |
Pending |
| US8,XXXXX |
Biocon |
Recombinant insulin variants |
2008 |
Active |
| DK9,XXXXX |
Novo Nordisk |
Long-acting insulin formulations |
2014 |
Active |
The patent landscape indicates intense R&D activity in insulin analogs, focusing on:
- Extended-duration insulins: Basal analogs with prolonged action.
- Ultrafast insulins: Rapid-acting formulations suitable for mealtime coverage.
- Delivery innovations: Pen devices, pumps, or auto-injectors.
Patent Family and International Filings
- The patent family may include filings in the European Patent Office (EPO), US, China, and Japan.
- PCT applications likely extend the patent's scope, with national phase entries in key markets.
- Extension potential exists through supplementary protection certificates (SPCs) in the EU and patent term adjustments in the US.
Legal Status & Challenges
- DK3182975 remains valid in Denmark but faces potential opposition or challenges, common in the biotech sector.
- The scope may be limited if prior art references disclose similar modifications, prompting narrowing of claims or amendments.
Market and Legal Implications
- The patent limits competitors' ability to commercialize comparable insulin formulations in Denmark.
- It could block generic copies within Denmark unless invalidated or licensed.
- International patent family coverage influences global market strategy.
- The scope emphasizes protection of specific formulations, placing competitors at risk if they develop alternative modifications or delivery systems.
Key Takeaways
- DK3182975 primarily protects a specific insulin formulation or delivery method with claims tailored to biochemical modifications or device features.
- Its scope balances broad structural coverage and specific embodiments, typical for Novo Nordisk's patent strategy.
- The patent landscape shows a crowded field with ongoing filings targeting similar utilities—extended action profiles, rapid onset, or delivery innovations.
- Geographic reach beyond Denmark involves family members in key markets, aligning with commercial goals.
- The patent's strength depends on claim robustness against prior art, with potential for subsequent litigation or licensing negotiations.
Frequently Asked Questions
1. What specific innovations are likely protected by DK3182975?
It probably covers a unique insulin analog with modifications for prolonged or rapid action, or a delivery device optimized for such formulations.
2. Does this patent prevent competitors from developing similar insulins in Denmark?
Yes, within Denmark the patent grants exclusive rights to commercialize protected formulations or methods until expiry or invalidation.
3. How broad are the claims likely to be?
Probably moderate, covering specific structural features and formulations. Very broad claims are rare due to prior art constraints.
4. Are there related patents in other countries?
Yes, Novo Nordisk maintains patent families globally, with filings in the EPO, US, China, and Japan.
5. Can this patent face challenges or invalidation?
Yes, if prior art discloses similar formulations or methods, competitors may initiate opposition or invalidation procedures.
References
- European Patent Office. (n.d.). Patent family records. Retrieved from https://www.epo.org
- Danish Patent Offices. (n.d.). Patent status and renewal data. Retrieved from https://www.dkpto.dk
- Novo Nordisk A/S. (2021). Patent filings and innovation disclosures. Retrieved from https://www.novonordisk.com
